Chongqing Lummy Pharmaceutical (300006) Stock Overview
Engages in the research and development, manufacture, and sale of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
300006 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Chongqing Lummy Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.06 |
| 52 Week High | CN¥6.43 |
| 52 Week Low | CN¥2.27 |
| Beta | 0.53 |
| 1 Month Change | 36.39% |
| 3 Month Change | 52.87% |
| 1 Year Change | 117.17% |
| 3 Year Change | 17.67% |
| 5 Year Change | -3.07% |
| Change since IPO | 1.77% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Chongqing Lummy Pharmaceutical (SZSE:300006) Use Debt?
Dec 30
Some Confidence Is Lacking In Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) As Shares Slide 26%
Dec 30Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%
Nov 15We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative
Oct 29Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%
Oct 01What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You
Oct 01Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)
Feb 27Shareholder Returns
| 300006 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 26.2% | 5.3% | 1.3% |
| 1Y | 117.2% | 30.2% | 26.0% |
Return vs Industry: 300006 exceeded the CN Pharmaceuticals industry which returned 29.3% over the past year.
Return vs Market: 300006 exceeded the CN Market which returned 26% over the past year.
Price Volatility
| 300006 volatility | |
|---|---|
| 300006 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 300006's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300006's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,019 | Rongzhao Qiu | www.cqlummy.com |
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd.
Chongqing Lummy Pharmaceutical Co., Ltd. Fundamentals Summary
| 300006 fundamental statistics | |
|---|---|
| Market cap | CN¥5.34b |
| Earnings (TTM) | -CN¥97.00m |
| Revenue (TTM) | CN¥812.87m |
Is 300006 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300006 income statement (TTM) | |
|---|---|
| Revenue | CN¥812.87m |
| Cost of Revenue | CN¥318.49m |
| Gross Profit | CN¥494.39m |
| Other Expenses | CN¥591.39m |
| Earnings | -CN¥97.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 22, 2025
| Earnings per share (EPS) | -0.092 |
| Gross Margin | 60.82% |
| Net Profit Margin | -11.93% |
| Debt/Equity Ratio | 18.6% |
How did 300006 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/18 11:53 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chongqing Lummy Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Changjiang Securities Co. LTD. |
| Chao Li | Citic Securities Co., Ltd. |
| Wen Liang Cui | Founder Securities Co., Ltd. |